{"protocolSection":{"identificationModule":{"nctId":"NCT06480981","orgStudyIdInfo":{"id":"DMX-NB-001"},"organization":{"fullName":"DemeRx NB","class":"INDUSTRY"},"briefTitle":"Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers","officialTitle":"A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Multiple Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ascending Doses of Noribogaine in Healthy Volunteers."},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-17","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-19","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"DemeRx NB","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This trial will be a randomised, double-blind, sequential-group, multiple-dose, placebo-controlled, dose escalation trial to characterise the pharmacokinetics (PK), pharmacodynamics (PD) and safety of noribogaine in healthy adult participants."},"conditionsModule":{"conditions":["Pharmacokinetics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"OTHER","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Noribogaine 20mg","type":"EXPERIMENTAL","description":"1 x Noribogaine 10mg capsule twice daily","interventionNames":["Drug: Noribogaine"]},{"label":"Noribogaine 40mg","type":"EXPERIMENTAL","description":"1 x Noribogaine 20mg capsule twice daily","interventionNames":["Drug: Noribogaine"]},{"label":"Noribogaine 60mg","type":"EXPERIMENTAL","description":"1 x Noribogaine 10mg capsule and 1 x Noribogaine 20mg capsule twice daily","interventionNames":["Drug: Noribogaine"]},{"label":"Noribogaine 80mg","type":"EXPERIMENTAL","description":"2 x Noribogaine 20mg capsule twice daily","interventionNames":["Drug: Noribogaine"]}],"interventions":[{"type":"DRUG","name":"Noribogaine","description":"Noribogaine capsules","armGroupLabels":["Noribogaine 20mg","Noribogaine 40mg","Noribogaine 60mg","Noribogaine 80mg"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Pharmacokinetics Cmax","description":"Determination of maximum plasma concentration of noribogaine","timeFrame":"Day 1 to Day 8"},{"measure":"Pharmacokinetics Tmax","description":"Determination of the time to reach the maximum plasma concentration of noribogaine","timeFrame":"Day 1 to Day 8"},{"measure":"Pharmacokinetics AUC0-t","description":"Determination of the area under the plasma concentration-time curve from time 0 to t of noribogaine","timeFrame":"Day 1 to Day 8"},{"measure":"Pharmacokinetics AUC0-infinity","description":"Determination of the area under the plasma concentration-time curve from time 0 to infinity of noribogaine","timeFrame":"Day 1 to Day 8"},{"measure":"Pharmacokinetics t1/2","description":"Determination of elimination half-life (t1/2) of noribogaine","timeFrame":"Day 1 to Day 8"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability to provide written, personally signed, and dated informed consent.\n* Healthy male and female participants between the ages of 18 to 45 inclusive.\n* BMI 18 - 30 kg/m2.\n* Non- or ex-smoker.\n* Normal ECG findings i.e. QTcF interval â‰¤ 450 ms and normal morphology that would permit accurate assessment of the QT interval.\n* Participants must agree to use highly\n\nExclusion Criteria:\n\n* History of, or concurrent clinically significant cardiovascular, dysautonomia, gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic or psychiatric, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the participant or impact the validity of the study.\n* Family history in first degree relatives for unknown and/or known arrhythmia-related cardiac events, cardiomyopathy, syncope, long QT syndrome, Brugada's syndrome, sudden death attributed to cardiac causes, and familial cardiac channelopathies.\n* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with interpretation of QTc interval changes.\n* Previous or current alcohol, or other drug dependence.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Jorg Taubel","role":"CONTACT","phone":"020 7042 5800","email":"info@richmondpharmacology.com"}],"overallOfficials":[{"name":"Jorg Taubel","affiliation":"Richmond Pharmacology","role":"PRINCIPAL_INVESTIGATOR"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"}},"hasResults":false}